Stocks and Investing Stocks and Investing
Fri, January 31, 2025
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of LENZ at $2 .. 9, after crossing above the $26.843 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of CSPI at $1 .. 4, after crossing above the $18.842 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of RGEN at $1 .. , after crossing above the $169.195 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of OCUL at $7 .. 97, after crossing above the $7.831 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of BCRX at $7 .. 45, after crossing above the $7.908 Trigger Price
[ Last Friday ] - MoneyWeek
Is now a good time to invest in infrastructure?
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of CHGCF at $ .. 1, after crossing above the $44.115 Trigger Price
[ Last Friday ] - MSN
Is It Worth Investing in Dell Technologies (DELL) Based on Wall Street's Bullish Views?
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of GSAT at $1 .. 85, after crossing above the $1.576 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of GRLRF at $ .. 71, after crossing above the $0.648 Trigger Price
[ Last Friday ] - Kiplinger
Intel Earnings Do Little to Excite Investors: What to Know
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of TMQ at $1.28, after crossing above the $1.272 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of STKL at $7 .. 54, after crossing above the $7.502 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of VYNE at $2 .. 439, after crossing above the $2.41 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of VIV at $8.87, after crossing above the $8.789 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of VIAV at $1 .. 9, after crossing above the $12.273 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of TREX at $7 .. 5, after crossing above the $74.291 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of SPND at $2 .. 49, after crossing above the $2.464 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of SIGI at $8 .. 4, after crossing above the $83.112 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of SETO at $0 .. 37, after crossing above the $0.028 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of PMNT at $1.1, after crossing above the $1.078 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of MKSI at $1 .. , after crossing above the $113.422 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of MAPSW at $ .. 09, after crossing above the $0.073 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of HUIZ at $3.5, after crossing above the $3.483 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of DPG at $11 .. 4, after crossing above the $11.831 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of CZNC at $2 .. 7, after crossing above the $21.452 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of CMTV at $1 .. 9, after crossing above the $17.641 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of ASCUF at $ .. 54, after crossing above the $1.145 Trigger Price
[ Last Friday ] - WOPRAI
Short squeeze is starting in shares of AP at $2.61, after crossing above the $2.581 Trigger Price
[ Last Friday ] - MSN
AbbVie stock rises on solid annual profit guidance, Q4 beat

AbbVie stock rises on solid annual profit guidance, Q4 beat


Published on 2025-01-31 10:21:23 - MSN
  Print publication without navigation

  • AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in immunology drugs Skyrizi and Rinvoq.

AbbVie Inc. experienced a rise in its stock price following the announcement of its solid annual profit guidance and a better-than-expected fourth-quarter performance. The company reported adjusted earnings of $2.79 per share, surpassing the consensus estimate of $2.76 per share, although its revenue of $14.3 billion fell short of the expected $14.5 billion. Despite the revenue miss, AbbVie's 2024 earnings per share guidance was set at $11.05 to $11.25, which was above the Wall Street consensus of $11.19. This optimistic outlook was driven by strong sales from its immunology drugs, particularly Skyrizi and Rinvoq, which are expected to offset the declining sales of Humira due to biosimilar competition. Additionally, AbbVie's CEO, Richard Gonzalez, highlighted the company's strategic focus on growth through its diversified portfolio and new product launches.

Read the Full MSN Article at:
[ https://www.msn.com/en-ca/money/top-stocks/abbvie-stock-rises-on-solid-annual-profit-guidance-q4-beat/ar-AA1ybFH9 ]
Contributing Sources